New hope for tiniest Babies' lungs
NCT ID NCT06855043
Summary
This study is testing the safety and initial effects of a special lung treatment given to extremely premature infants who are still on a breathing machine at 7-14 days old. The treatment combines surfactant, a substance that helps lungs stay open, with a steroid called budesonide, aiming to prevent a serious chronic lung condition common in preemies. Researchers will closely monitor 24 infants for immediate safety and changes in their breathing support needs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE MECHANICAL VENTILATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
American Family Children's Hospital
Madison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Meriter Hospital
Madison, Wisconsin, 53715, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.